Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 6/20 | 0.57 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.57 |
| ▸ | MMP2 | P08253 | 4/20 | 0.54 |
| ▸ | MMP8 | P22894 | 3/20 | 0.54 |
| ▸ | MMP1 | P03956 | 3/20 | 0.54 |
| ▸ | MMP9 | P14780 | 2/20 | 0.54 |
| ▸ | IL1RN | P18510 | 4/20 | 0.53 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30052459 | 0.96 | ECE1 (0.61) | ECE1ERAP2OPRM1OPRD1MMP2 | |
| SCHEMBL30307309 | 0.95 | OPRM1 (0.62) | ECE1ERAP2OPRM1OPRD1IL1RN | |
| SCHEMBL29376430 | 0.91 | OPRM1 (0.61) | ECE1ERAP2OPRM1OPRD1MMP2 | |
| SCHEMBL30051322 | 0.89 | ECE1 (0.64) | ECE1ERAP2OPRM1OPRD1MMP2 | |
| SCHEMBL30052868 | 0.87 | KDM4E (0.60) | ECE1OPRM1OPRD1MMP2MMP8 | |
| SCHEMBL7593998 | 0.87 | KDM4E (0.63) | OPRM1OPRD1 | |
| SCHEMBL11432177 | 0.87 | ERAP2 (0.56) | ERAP2OPRM1OPRD1MMP2MMP8 | |
| SCHEMBL30576704 | 0.87 | OPRM1 (0.68) | ERAP2OPRM1OPRD1IL1RNNPBWR1 | |
| SCHEMBL30576711 | 0.87 | OPRM1 (0.68) | ERAP2OPRM1OPRD1IL1RNNPBWR1 | |
| SCHEMBL29380319 | 0.87 | ERAP2 (0.64) | ECE1ERAP2MMP2MMP8MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | UNIVERSITY OF WARWICK (GB) | 2023-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | NGLY1, MAX, PTMA | ECE1 780/4885ERAP2 2626/4885OPRM1 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.